CLBS - Caladrius Biosciences Inc Stock Price, Fair Value and News

2.85USD-0.08 (-2.73%)Market Closed

Market Summary

USD2.85-0.08

Market Closed

-2.73%

CLBS Stock Price

View Fullscreen

CLBS RSI Chart

CLBS Valuation

Market Cap

23.7M

Price/Earnings (Trailing)

-1.14

Price/Sales (Trailing)

8.69

EV/EBITDA

-0.05

Price/Free Cashflow

-1.18

CLBS Price/Sales (Trailing)

CLBS Profitability

Operating Margin

-1109.84%

EBT Margin

-850.74%

Return on Equity

-43.28%

Return on Assets

-38.1%

Free Cashflow Yield

-84.61%

CLBS Fundamentals

CLBS Revenue

Revenue (TTM)

2.7M

Rev. Growth (Yr)

20.56%

Rev. Growth (Qtr)

-5.95%

CLBS Earnings

Earnings (TTM)

-20.8M

Earnings Growth (Yr)

10.43%

Earnings Growth (Qtr)

-1.98%

Breaking Down CLBS Revenue

Last 7 days

7.6%

Last 30 days

-6.6%

Last 90 days

2.9%

Trailing 12 Months

-38.5%

How does CLBS drawdown profile look like?

CLBS Financial Health

Current Ratio

8.18

CLBS Investor Care

Shares Dilution (1Y)

3.56%

Diluted EPS (TTM)

-2.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.7M	2.2M	2.6M	2.7M
2022	191.0K	238.0K	534.0K	1.1M
2021	117.5K	142.5K	158.5K	151.0K
2020	11.0K	30.0K	54.0K	98.5K
2019	17.9M	11.9M	6.0M	9.0K
2018	0	0	29.8M	23.8M
2017	35.7M	0	0	0
2016	26.8M	29.2M	32.7M	35.3M
2015	18.2M	18.4M	20.2M	22.5M
2014	0	15.8M	16.8M	17.9M
2013	0	14.4M	14.6M	14.7M
2012	12.4M	13.5M	15.8M	14.3M
2011	0	0	0	28.2M
2010	0	0	0	0
2009	0	0	0	11.6M
2008	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Caladrius Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 01, 2022	mazzo david j	acquired	75,000	0.5	150,000	chief executive officer
Sep 01, 2022	buck kristen k	sold (taxes)	-34,979	0.5	-69,959	evp, r&d and cmo
Sep 01, 2022	buck kristen k	acquired	29,000	0.5	58,000	evp, r&d and cmo
Sep 01, 2022	mazzo david j	sold (taxes)	-34,871	0.5	-69,742	chief executive officer
Jan 14, 2022	girolamo todd c	sold (taxes)	-1,770	0.8204	-2,158	clo, svp of corp dev
Jan 14, 2022	mazzo david j	sold (taxes)	-5,423	0.8204	-6,611	chief executive officer
Jan 13, 2022	mazzo david j	sold (taxes)	-5,217	0.8063	-6,471	chief executive officer
Jan 13, 2022	girolamo todd c	sold (taxes)	-2,066	0.8063	-2,563	clo, svp of corp dev
Jan 11, 2022	girolamo todd c	sold (taxes)	-4,085	0.8651	-4,722	clo, svp of corp dev
Jan 11, 2022	mazzo david j	sold (taxes)	-14,481	0.8651	-16,740	chief executive officer

Which funds bought or sold CLBS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 24, 2024	BML Capital Management, LLC	added	5.5	151,507	888,167	0.59%
Apr 10, 2024	Founders Capital Management	unchanged	-	130	1,039	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.47	106,176	483,114	-%
Feb 15, 2024	BARCLAYS PLC	unchanged	-	-	-	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	9,183	39,170	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-0.23	5,653	26,377	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	92,135	92,135	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	reduced	-23.95	-258	38,578	-%

Are Funds Buying or Selling CLBS?

Are funds buying CLBS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CLBS

No. of Funds

Unveiling Caladrius Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2022	cvi investments, inc.	2.6%	1,575,000	SC 13G/A
Feb 10, 2022	renaissance technologies llc	2.68%	1,600,655	SC 13G/A
Feb 04, 2022	mmcap international inc. spc	2.79%	1,714,286	SC 13G/A
Jan 19, 2022	empery asset management, lp	4.02%	2,505,367	SC 13G/A
Feb 24, 2021	cvi investments, inc.	-	3e+06	SC 13G
Feb 22, 2021	intracoastal capital, llc	1.6%	949,609	SC 13G
Feb 22, 2021	mmcap international inc. spc	9.99%	5,142,858	SC 13G
Feb 18, 2021	empery asset management, lp	5.90%	3,448,980	SC 13G
Feb 16, 2021	armistice capital, llc	4.0%	801,148	SC 13G/A
Feb 10, 2021	renaissance technologies llc	5.39%	1,045,855	SC 13G

Recent SEC filings of Caladrius Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 01, 2024	S-3	S-3
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Apr 24, 2024	3	Insider Trading
Apr 17, 2024	8-K	Current Report
Mar 28, 2024	ARS	ARS
Feb 29, 2024	8-K	Current Report
Feb 29, 2024	10-K	Annual Report

Caladrius Biosciences Inc News

Latest updates

Caladrius Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-6.0%	671,500	714,000	668,000	670,000	557,000	337,000	94,000	63,000	40,000	41,000	47,000	23,000	47,500	25,000	22,000	4,000	3,000	1,000	3,000	1,982,917	3,962,834
Operating Expenses	1.0%	6,025,000	5,964,000	6,875,000	6,844,000	6,540,500	37,720,000	6,720,000	6,620,000	6,849,000	6,968,000	7,147,000	8,086,000	5,446,000	5,350,000	4,292,000	4,057,000	5,082,000	5,072,000	5,346,000	4,592,000	3,796,000
S&GA Expenses	16.6%	3,012,000	2,584,000	3,713,000	3,665,000	3,326,000	3,992,000	3,486,000	3,337,000	2,803,000	2,843,000	2,818,000	3,010,000	2,539,000	2,321,000	2,474,000	2,558,000	2,315,000	2,068,000	2,358,000	2,554,000	2,288,000
R&D Expenses	-	-	-	-	-	-	-	3,239,000	3,278,000	4,150,000	4,125,000	4,329,000	5,076,000	2,907,000	3,029,000	1,818,000	1,499,000	2,767,000	3,004,000	2,988,000	2,038,000	1,508,000
EBITDA Margin	6.7%	-8.44	-9.05	-24.99	-33.82	-53.89	-107	-113	-144	-191	-173	-182	-195	-192	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-2,330,000	-	-	-	-	-2,479,000	-	-	-1,508,000	-	-	-	-10,872,000	-	-	-	-	-	-
Earnings Before Taxes	-2.0%	-5,365,000	-5,261,000	-6,357,000	-6,187,000	-5,990,000	-37,383,000	-6,626,000	-6,705,000	-6,794,000	-6,927,000	-7,190,000	-8,063,000	-5,432,000	-5,325,000	-4,270,000	-	-4,953,000	-4,897,000	-5,137,000	-	-3,557,143
EBT Margin	6.7%	-8.51	-9.12	-25.05	-33.89	-53.95	-107	-113	-144	-191	-174	-182	-196	-193	-	-	-	-	-	-	-	-
Net Income	-2.0%	-5,365,000	-5,261,000	-4,027,000	-6,187,000	-5,990,000	-37,383,000	-6,626,000	-4,226,000	-6,794,000	-6,927,000	-5,682,000	-8,063,000	-5,431,000	-5,327,000	6,598,000	-3,990,000	-4,956,000	-4,898,000	-5,140,000	-4,367,000	-3,556,500
Net Income Margin	7.0%	-7.65	-8.23	-24.01	-33.89	-51.59	-103	-103	-123	-181	-164	-171	-104	-82.74	-	-	-	-	-	-	-	-
Free Cashflow	-13.6%	-4,069,000	-3,583,000	-4,210,000	-8,222,000	-6,494,000	-4,022,000	-5,062,000	-5,642,000	-4,604,000	-5,039,000	-4,687,000	-7,975,000	-5,573,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.8%	55.00	58.00	62.00	66.00	73.00	79.00	86.00	91.00	97.00	103	109	115	36.00	42.00	37.00	22.00	27.00	32.00	36.00	41.00	45.00
Current Assets	-5.8%	54.00	57.00	61.00	65.00	72.00	77.00	75.00	91.00	96.00	102	108	114	35.00	41.00	37.00	21.00	26.00	30.00	35.00	40.00	44.00
Cash Equivalents	-30.3%	23.00	32.00	24.00	28.00	32.00	31.00	33.00	13.00	25.00	13.00	13.00	29.00	17.00	21.00	27.00	21.00	14.00	13.00	12.00	14.00	10.00
Net PPE	-14.2%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	26.3%	7.00	5.00	5.00	6.00	7.00	7.00	4.00	3.00	5.00	4.00	4.00	5.00	4.00	5.00	4.00	5.00	7.00	7.00	7.00	7.00	7.00
Current Liabilities	28.4%	7.00	5.00	4.00	5.00	6.00	6.00	3.00	3.00	5.00	4.00	4.00	4.00	4.00	4.00	3.00	5.00	6.00	6.00	6.00	5.00	6.00
Shareholder's Equity	-9.1%	48.00	53.00	58.00	61.00	67.00	72.00	82.00	88.00	92.00	98.00	105	110	32.00	37.00	34.00	17.00	21.00	25.00	30.00	34.00	37.00
Retained Earnings	-1.0%	-528	-522	-517	-513	-507	-501	-463	-457	-453	-446	-439	-433	-425	-420	-414	-421	-417	-412	-407	-402	-397
Additional Paid-In Capital	0.1%	577	576	576	575	575	574	547	547	546	546	545	545	459	459	449	439	439	438	438	438	436
Shares Outstanding	0.1%	8.00	8.00	8.00	8.00	8.00	5.00	4.00	4.00	4.00	4.00	4.00	3.00	1.00	-	-	-	-	-	-	-	-
Minority Interest	0%	-0.25	-0.25	-0.25	-0.25	-0.25	-0.25	-0.25	-0.25	-0.25	-0.25	-0.25	-0.25	-0.25	-0.25	-0.25	-0.26	-0.26	-0.27	-0.27	-0.27	-0.27
Float	-	-	-	25.00	-	-	-	31.00	-	-	-	95.00	-	-	-	27.00	-	-	-	20.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-13.6%	-4,069	-3,583	-4,184	-8,196	-6,468	-3,998	-5,062	-5,642	-4,604	-5,039	-4,627	-7,975	-5,567	-3,518	4,503	-4,241	-4,220	-4,457	-4,719	-5,486	-3,042
Cashflow From Investing	-146.6%	-5,714	12,252	-725	4,289	7,106	2,261	25,634	-6,090	16,458	4,940	-11,204	-65,090	910	-11,042	-8,247	11,102	5,303	5,377	2,011	8,741	-1,066
Cashflow From Financing	500.0%	24.00	-6.00	452	-85.00	14.00	-99.00	29.00	-168	21.00	-64.00	22.00	85,297	13.00	9,032	9,683	-148	275	-	38.00	870	33.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CLBS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Expenses:
Research and development	$ 12,734	$ 13,067
In-process research and development	0	30,393
General and administrative	12,974	14,141
Operating expenses	25,708	57,601
Operating loss	(25,708)	(57,601)
Other income (expense):
Investment income, net	2,724	1,052
Other expense, net	(186)	(155)
Total other income	2,538	897
Net loss before benefit from income taxes and noncontrolling interests	(23,170)	(56,704)
Benefit from income taxes	(2,330)	(2,479)
Net loss	(20,840)	(54,225)
Less - net income (loss) attributable to noncontrolling interests	0	0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders	$ (20,840)	$ (54,225)
Basic and diluted loss per share:
Lisata Therapeutics, Inc. common stockholders - basic (in dollars per share)	$ (2.58)	$ (10.47)
Lisata Therapeutics, Inc. common stockholders - diluted (in dollars per share)	$ (2.58)	$ (10.47)
Weighted average common shares outstanding:
Basic (in shares)	8,073	5,180
Diluted (in shares)	8,073	5,180

CLBS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 22,593	$ 32,154
Marketable securities	27,942	37,072
Prepaid and other current assets	3,389	2,650
Total current assets	53,924	71,876
Property and equipment, net	175	296
Acquired license-intangible, net	263	334
Other assets	332	528
Total assets	54,694	73,034
Liabilities
Accounts payable	2,421	2,655
Accrued liabilities	4,169	3,728
Total current liabilities	6,590	6,383
Other long-term liabilities	210	327
Total liabilities	6,800	6,710
Commitments and Contingencies (Note 14)
Stockholders' Equity
Common stock, $0.001 par value, authorized 33,333,333 shares; issued 8,150,635 and 7,866,799 shares, at December 31, 2023 and December 31, 2022, respectively; and outstanding, 8,149,897 and 7,866,061 shares, at December 31, 2023 and December 31, 2022, respectively	8	8
Additional paid-in capital	576,971	574,548
Treasury stock, at cost; 738 shares at December 31, 2023 and December 31, 2022 respectively	(708)	(708)
Accumulated deficit	(528,081)	(507,241)
Accumulated other comprehensive loss	(42)	(29)
Total Lisata Therapeutics, Inc. stockholders' equity	48,148	66,578
Non-controlling interests	(254)	(254)
Total equity	47,894	66,324
Total liabilities, non-controlling interests and stockholders' equity	$ 54,694	$ 73,034

About Caladrius Biosciences Inc

WEBSITE	caladrius.com

Caladrius Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Caladrius Biosciences Inc? What does CLBS stand for in stocks?

CLBS is the stock ticker symbol of Caladrius Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Caladrius Biosciences Inc (CLBS)?

As of Fri May 03 2024, market cap of Caladrius Biosciences Inc is 23.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLBS stock?

You can check CLBS's fair value in chart for subscribers.

What is the fair value of CLBS stock?

You can check CLBS's fair value in chart for subscribers. The fair value of Caladrius Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Caladrius Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLBS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Caladrius Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether CLBS is over valued or under valued. Whether Caladrius Biosciences Inc is cheap or expensive depends on the assumptions which impact Caladrius Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLBS.

What is Caladrius Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, CLBS's PE ratio (Price to Earnings) is -1.14 and Price to Sales (PS) ratio is 8.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLBS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Caladrius Biosciences Inc's stock?

In the past 10 years, Caladrius Biosciences Inc has provided -0.262 (multiply by 100 for percentage) rate of return.